PD45-10 CELL-BASED MOLECULAR THERAPY FOR CHRONIC KIDNEY TUBULOINTERSTITIAL FIBROSIS

You have accessJournal of UrologyRenal Transplantation & Vascular Surgery II (PD45)1 Sep 2021PD45-10 CELL-BASED MOLECULAR THERAPY FOR CHRONIC KIDNEY TUBULOINTERSTITIAL FIBROSIS Julie Bennington, Shannon Lankford, Gopal Badlani, and J. Williams BenningtonJulie Bennington More articles by this author , LankfordShannon Lankford BadlaniGopal Badlani WilliamsJ. View All Author Informationhttps://doi.org/10.1097/JU.0000000000002059.10AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Chronic, irreversible tubulointerstitial fibrosis (TIF) is a common final pathway leading end stage kidney disease. There no effective cure; however, cell-based molecules may be promising approach reverse renal fibrosis. The goal study test the use cell-signaling chemokine CXCL12 in reversing cat model unilateral ischemia/reperfusion (I/R)-induced METHODS: In model, 30 adult female cats received an intra-renal injection 100, 200, or 400 ng recombinant human CXCL12, sterile saline, into I/R 70 days post- injury, were non-injured, non-injected controls (n=6/treatment condition). Kidney collagen content was quantified 4 months post saline using Masson’s Trichrome Picrosirius Red - stained tissues. additional pilot study, with assessed minutes 1 week post-CXCL12 for expression matrix metaloproteinase-1 (MMP-1), LOXL-2 (associated cross-linking) CXCL12; ELISA analysis kidney. RESULTS: increased affected content, which both mid high doses restored normal (p<.05 vs. untreated) (Figure 1). fiber width, (p<.001 Early changes (increased MMP-1) CXCL12), (decreased LOX-2) not seen injection. CONCLUSIONS: Local reverses formation TIF dose dependent manner. Its early effects on affecting breakdown cross-linking alter metabolism, resulting reduced Additional mechanistic, long-term efficacy safety studies are needed. Source Funding: NIH, NIDDK; T32, Piedmont Animal Health © 2021 American Urological Association Education Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e745-e746 Advertisement Copyright Permissions© Inc.MetricsAuthor Information Expand Loading ...